Insider Buying: SCYNEXIS Inc (NASDAQ:SCYX) CEO Purchases $10,115.15 in Stock

SCYNEXIS Inc (NASDAQ:SCYX) CEO Marco Taglietti acquired 10,015 shares of SCYNEXIS stock in a transaction that occurred on Thursday, August 15th. The stock was bought at an average price of $1.01 per share, with a total value of $10,115.15. Following the purchase, the chief executive officer now directly owns 516,015 shares of the company’s stock, valued at $521,175.15. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of SCYX opened at $1.15 on Thursday. The company has a current ratio of 4.99, a quick ratio of 4.99 and a debt-to-equity ratio of 1.73. The stock has a market cap of $59.61 million, a P/E ratio of -2.35 and a beta of 2.31. The company has a 50-day moving average of $1.16 and a two-hundred day moving average of $1.34. SCYNEXIS Inc has a 12-month low of $0.35 and a 12-month high of $1.90.

SCYNEXIS (NASDAQ:SCYX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.06 million. SCYNEXIS had a negative net margin of 11,653.81% and a negative return on equity of 141.28%. As a group, analysts forecast that SCYNEXIS Inc will post -0.92 EPS for the current fiscal year.

Several brokerages recently commented on SCYX. Zacks Investment Research cut shares of SCYNEXIS from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. ValuEngine cut shares of SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Saturday, May 18th. Brookline Capital Management reiterated a “buy” rating on shares of SCYNEXIS in a research note on Monday. LADENBURG THALM/SH SH set a $6.00 price objective on shares of SCYNEXIS and gave the company a “buy” rating in a research note on Friday, May 24th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of SCYNEXIS in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. SCYNEXIS currently has a consensus rating of “Buy” and a consensus price target of $4.30.

A number of institutional investors and hedge funds have recently made changes to their positions in SCYX. Vanguard Group Inc. raised its position in SCYNEXIS by 47.7% during the second quarter. Vanguard Group Inc. now owns 2,373,737 shares of the company’s stock worth $3,110,000 after acquiring an additional 766,865 shares during the last quarter. BlackRock Inc. raised its position in SCYNEXIS by 152.0% during the second quarter. BlackRock Inc. now owns 854,880 shares of the company’s stock worth $1,121,000 after acquiring an additional 515,707 shares during the last quarter. Deutsche Bank AG acquired a new position in SCYNEXIS during the fourth quarter worth about $121,000. Renaissance Technologies LLC raised its position in SCYNEXIS by 86.1% during the second quarter. Renaissance Technologies LLC now owns 475,315 shares of the company’s stock worth $623,000 after acquiring an additional 219,900 shares during the last quarter. Finally, Bailard Inc. acquired a new position in SCYNEXIS during the first quarter worth about $196,000. Institutional investors own 31.55% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.

Read More: What is the Producer Price Index (PPI)?

Insider Buying and Selling by Quarter for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit